Keywords: Biovest Int, BiovaxID, Cancer vaccine, Mantle cell lymphoma, ersonalized medicine
Biovest sees mantle cell lymphoma as next target indication for personalized cancer vaccine
Article | 25 June 2010
Florida, USA-based Biovest International yesterday announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that it is targeting mantle cell ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
